[
  {
    "ts": "2026-01-15T12:22:02+00:00",
    "headline": "Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade",
    "summary": "Jan 15 (Reuters) - Boston Scientific is buying medical equipment maker Penumbra in a deal valued at about $14.5 billion, to expand its vascular pipeline.",
    "url": "https://finance.yahoo.com/news/factbox-major-deals-involving-u-122202362.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "98831ded-5316-3639-8b32-bf5b84c462f3",
      "content": {
        "id": "98831ded-5316-3639-8b32-bf5b84c462f3",
        "contentType": "STORY",
        "title": "Factbox-Major deals involving U.S. drugmakers and biotechs over the past decade",
        "description": "",
        "summary": "Jan 15 (Reuters) - Boston Scientific is buying medical equipment maker Penumbra in a deal valued at about $14.5 billion, to expand its vascular pipeline.",
        "pubDate": "2026-01-15T12:22:02Z",
        "displayTime": "2026-01-15T12:22:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/factbox-major-deals-involving-u-122202362.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/factbox-major-deals-involving-u-122202362.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PEN"
            },
            {
              "symbol": "BSX"
            },
            {
              "symbol": "EXAS"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-15T16:55:56+00:00",
    "headline": "Dividend King Abbott Shows Why 52 Consecutive Increases Weren’t Luck With Strong Cash Flow Coverage",
    "summary": "Abbott Laboratories (NYSE: ABT) doesn’t just pay dividends. It grows them. For 52 consecutive years. That’s Dividend King territory, and the streak isn’t in danger. The company just raised its quarterly dividend to $0.63 in January 2026, a 6.8% increase from the prior $0.59 rate. That puts the annual payout at $2.52 per share with ... Dividend King Abbott Shows Why 52 Consecutive Increases Weren’t Luck With Strong Cash Flow Coverage",
    "url": "https://247wallst.com/investing/2026/01/15/dividend-king-abbott-shows-why-52-consecutive-increases-werent-luck-with-strong-cash-flow-coverage/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "12132598-6516-3569-9097-4841d6b402fc",
      "content": {
        "id": "12132598-6516-3569-9097-4841d6b402fc",
        "contentType": "STORY",
        "title": "Dividend King Abbott Shows Why 52 Consecutive Increases Weren’t Luck With Strong Cash Flow Coverage",
        "description": "",
        "summary": "Abbott Laboratories (NYSE: ABT) doesn’t just pay dividends. It grows them. For 52 consecutive years. That’s Dividend King territory, and the streak isn’t in danger. The company just raised its quarterly dividend to $0.63 in January 2026, a 6.8% increase from the prior $0.59 rate. That puts the annual payout at $2.52 per share with ... Dividend King Abbott Shows Why 52 Consecutive Increases Weren’t Luck With Strong Cash Flow Coverage",
        "pubDate": "2026-01-15T16:55:56Z",
        "displayTime": "2026-01-15T16:55:56Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/c3fbaf870eaec489de89e20299f06ae7",
          "originalWidth": 1366,
          "originalHeight": 768,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/GjE1_sW98nU83DY.bup5rQ--~B/aD03Njg7dz0xMzY2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/c3fbaf870eaec489de89e20299f06ae7.cf.webp",
              "width": 1366,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0CRJcmTB4ZztQHqQk_84ow--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/c3fbaf870eaec489de89e20299f06ae7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/01/15/dividend-king-abbott-shows-why-52-consecutive-increases-werent-luck-with-strong-cash-flow-coverage/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/dividend-king-abbott-shows-why-165556718.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]